Tag: immune checkpoint
-
Checkpoint Inhibitor TIGIT Promotes Tissue Repair
New role for checkpoint inhibitors in tissue healing Checkpoint inhibitors are best known for unleashing the immune system against cancer. A surprising new perspective emerging from researchers at the University of Zurich (UZH) shows that one of these inhibitors, TIGIT, also plays a vital part in tissue repair. Published in Nature Immunology, the study reveals…
-
TIGIT: Immune Checkpoint Promoter of Tissue Healing Could Change Fibrosis and Wound Care
Groundbreaking finding: TIGIT helps tissue repair Researchers at the University of Zurich (UZH) have uncovered a surprising role for the immune checkpoint inhibitor TIGIT beyond its well-known function as a cancer therapy target. In a study led by Nicole Joller, the team demonstrated that TIGIT not only helps regulate immune responses during infections but also…
-
TIGIT Promotes Tissue Healing: A New Role for Immune Checkpoints
Unlocking a Hidden Role for Immune Checkpoints Immune checkpoint inhibitors are best known as cancer therapies that unleash the body’s defenses against tumors. A team from the University of Zurich (UZH) has uncovered a surprising new function for one of these molecules: TIGIT, a surface receptor on immune cells, also promotes tissue healing after viral…
-
TIGIT Immune Checkpoint Promotes Tissue Healing and Regeneration
Overview: A new role for an immune checkpoint Immune checkpoint inhibitors have transformed cancer therapy by releasing the brakes on the immune system. A surprising new finding from researchers at the University of Zurich (UZH) reveals that one such brake, TIGIT, does more than help tumor-fighting immune cells—it also promotes tissue healing. This discovery could…
-
Avelumab with Radiation for Leptomeningeal Disease: Momentum
Introduction Leptomeningeal disease, in which cancer cells invade the membranes surrounding the brain and spinal cord, remains one of oncology’s most daunting challenges. Patients face rapid neurological decline, and survival is often measured in weeks to months. In a phase 1B study from Moffitt Cancer Center, researchers explored whether combining the immunotherapy drug avelumab with…
-
Avelumab with Radiation: Hope for Leptomeningeal Disease
Leptomeningeal disease: a high-stakes challenge in oncology Leptomeningeal disease, where cancer cells spread to the membranes surrounding the brain and spinal cord, remains one of oncology’s most formidable complications. Patients diagnosed with this condition often face survival measured in weeks to months, and treatment options are historically limited. In a hopeful development, researchers at Moffitt…